FI970825A0 - Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria - Google Patents

Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria

Info

Publication number
FI970825A0
FI970825A0 FI970825A FI970825A FI970825A0 FI 970825 A0 FI970825 A0 FI 970825A0 FI 970825 A FI970825 A FI 970825A FI 970825 A FI970825 A FI 970825A FI 970825 A0 FI970825 A0 FI 970825A0
Authority
FI
Finland
Prior art keywords
buffer
pharmaceutical compositions
active compound
compositions containing
bile salt
Prior art date
Application number
FI970825A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970825A (fi
Inventor
Roger Randal Charles New
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of FI970825A publication Critical patent/FI970825A/fi
Publication of FI970825A0 publication Critical patent/FI970825A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI970825A 1994-08-31 1997-02-27 Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria FI970825A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9417524A GB9417524D0 (en) 1994-08-31 1994-08-31 Pharmaceutical compositions
PCT/GB1995/002015 WO1996006635A1 (en) 1994-08-31 1995-08-25 Pharmaceutical compositions containing a bile salt and a buffer for increased bioavailability of an active compound

Publications (2)

Publication Number Publication Date
FI970825A FI970825A (fi) 1997-02-27
FI970825A0 true FI970825A0 (fi) 1997-02-27

Family

ID=10760623

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970825A FI970825A0 (fi) 1994-08-31 1997-02-27 Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria

Country Status (13)

Country Link
US (1) US5853748A (de)
EP (1) EP0769960A1 (de)
JP (1) JPH10504835A (de)
KR (1) KR970705406A (de)
AU (1) AU705123B2 (de)
CA (1) CA2198721A1 (de)
FI (1) FI970825A0 (de)
GB (1) GB9417524D0 (de)
IL (1) IL115097A0 (de)
NO (1) NO970894D0 (de)
NZ (1) NZ291863A (de)
WO (1) WO1996006635A1 (de)
ZA (1) ZA957247B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295176T1 (de) 1997-05-19 2005-05-15 Repligen Corp Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
EP1012331B1 (de) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
EP1080103A4 (de) * 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
WO1999065493A1 (en) * 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US9357797B2 (en) 1999-11-06 2016-06-07 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US20030235629A1 (en) * 1999-11-06 2003-12-25 Janmarie Hornack Dietary supplement containing alkaline electrolyte buffers
US20030003537A1 (en) * 2001-04-30 2003-01-02 Ventana Medical Systems, Inc. Method and composition of matter for enhancing staining of microorganisms
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
JP5462429B2 (ja) 2002-01-16 2014-04-02 アステラス製薬株式会社 経口吸収改善用医薬組成物
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
ATE500821T1 (de) 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
BRPI0418228B8 (pt) * 2003-12-31 2021-05-25 Cima Labs Inc forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
CA2563533C (en) * 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
MX2008004674A (es) * 2005-10-13 2008-11-12 Biocon Ltd Proceso para la preparacion de conjugados de insulina.
KR100700948B1 (ko) * 2006-05-25 2007-03-28 삼성전자주식회사 이동통신 시스템에서 무선 랜의 다중 채널을 이용하는데이터 전송 장치 및 방법
EP2203181B1 (de) 2007-10-16 2018-02-14 Biocon Limited Oral zu verabreichende feste pharmazeutische zusammensetzung und verfahren dafür
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20100105627A1 (en) 2008-09-17 2010-04-29 Paul Salama Pharmaceutical compositions and related methods of delivery
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2675460A4 (de) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc Behandlung von fettgewebe unter dem kinn
NZ727407A (en) 2014-06-27 2018-12-21 Medytox Inc Methods and compositions of bile acids and salts for reduction of fat
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GB2625490A (en) * 2021-01-27 2024-06-19 D&D Pharmatech Inc Pharmaceutical composition comprising large physiologically active substance and excipient
AU2022344774A1 (en) * 2021-09-07 2024-03-14 D&D Pharmatech Inc. Pharmaceutical composition comprising large physiologically active substance and excipient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
JPH04149126A (ja) * 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
DE4234537A1 (de) * 1992-10-14 1994-04-21 Hoechst Ag Zubereitung, enthaltend Insulin und polymere Gallensäure

Also Published As

Publication number Publication date
CA2198721A1 (en) 1996-03-07
NO970894L (no) 1997-02-27
AU705123B2 (en) 1999-05-13
KR970705406A (ko) 1997-10-09
ZA957247B (en) 1997-02-28
MX9701455A (es) 1998-05-31
IL115097A0 (en) 1996-01-19
FI970825A (fi) 1997-02-27
AU3351095A (en) 1996-03-22
GB9417524D0 (en) 1994-10-19
NO970894D0 (no) 1997-02-27
EP0769960A1 (de) 1997-05-02
WO1996006635A1 (en) 1996-03-07
US5853748A (en) 1998-12-29
JPH10504835A (ja) 1998-05-12
NZ291863A (en) 1998-12-23

Similar Documents

Publication Publication Date Title
FI970825A0 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
FI973518A0 (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
NO974495L (no) Forbindelse og sammensetninger for levering av aktive midler
FI973426A (fi) Bentsopyraania sisältävät yhdisteet ja menetelmä niiden valmistamiseksi
FR2786771B1 (fr) Procede de stabilisation d'un macrolide poly-ene et composition pharmaceutique contenant un tel compose
FI945731A0 (fi) Tiatsolidiinijohdannaiset ja farmaseuttiset koostumukset, jotka sisältävät niitä
MA23632A1 (fr) Procede de preparation de composes nouveaux et de compostions pharmaceutiques les contenant
FI93680C (fi) Ohutkalvon tukirakenne ja menetelmä sen valmistamiseksi
CY2005007I2 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
PT589843E (pt) Composicoes farmaceuticas contendo ciclosporinas
FI932932A0 (fi) Foerfarande och komposition foer desinfektering av kontaktlinser
FI941396A (fi) Koostumuksia biologisesti aktiivisen TGF-valvottua vapauttamista varten
FR2737122B1 (fr) Composition stable contenant de l'acide ascorbique
FR2764800B1 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
FI970099A0 (fi) 3-fenyylipyratsolijohdannaisia sisältävät fungisidiset koostumukset lisääntyvän kasvimateriaalin käsittelemiseksi, uudet 3-fenyylipyratsolijohdannaiset ja niiden fungisidinen käyttö
BE893193A (fr) Composition pharmaceutique contenant du 24-25-dihydroxy-cholecalciferol a titre d'ingredient actif
FI931582A0 (fi) Renat enzymkoncentrat och foerfaranden foer framstaellning av detta
FI971750A (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI955367A0 (fi) Kalantoukkien viljekyyn tarkoitettu toukkien kasvatuskaappi
ITMI921413A0 (it) Preparazioni farmaceutiche stabili di nicorandil
FI953369A (fi) Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi
FI97944B (fi) Vaikuttavaa ainetta luovuttava laite
FI930962A0 (fi) Anordning foer registrering av den malbara laddningens maengd i ett visst oegonblick i en malningstrumma
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FI962976A0 (fi) Viherkaihin hoitoon tarkoitettuja koostumuksia, jotka sisältävät beta-salpaajaa